Glycated serum albumin: A potential disease marker and an intermediate index of diabetes control

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 8, Issue 4, 2014, Pages 245-251

  Raghav, Alok ^a   Ahmad, Jamal ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Diabetes associated complications; Glycated serum albumin; Potential disease marker

Indexed keywords

GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HUMAN SERUM ALBUMIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SERUM ALBUMIN;

CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE MARKER; GLYCEMIC CONTROL; HUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; BLOOD; DIABETES COMPLICATIONS; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HYPERGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; SERUM ALBUMIN;

EID: 84916200684     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2014.09.017     Document Type: Review

References (49)

1. A. Arasteh, S. Farahi, M. Habibi-Rezael, and A.A. Moosavi-Movahedi Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker J Diabetes Metab Disord 13 2014 49
2. F.N. Ziyadeh Mediators of diabetic renal disease: the case for TGF-β as the major mediator J Am Soc Nephrol 15 Suppl. 1 2004 S55 S57
3. R.D. Harris, M.W. Steffes, R.W. Bilous, D.E. Sutherland, and S.M. Mauer Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes Kidney Int 40 1991 107 114
4. C.W. Heilig, L.A. Concepoion, B.L. Riser, S.O. Freytag, M. Zhu, and P. Cortes Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype J Clin Investig 96 1995 1802 1814
5. Z. Makita, S. Radoff, J.R. Elliot, Z. Yang, E. Skolnik, and V. Delaney Advanced glycosylation end products in patients with diabetic nephropathy N Engl J Med 325 1991 836 842
6. T.J. Berg, H.J. Bangstad, P.A. Torjesen, R. Osterby, R. Bucala, and K.F. Hanssen Advanced glycation end products in serum predicts changes in the kidney morphology of patients with insulin-dependent diabetes mellitus Metabolism 6 1997 661 665
7. T.P. Peacock, Z.K. Shihabi, A.J. Bleyer, E.L. Dolbare, J.R. Byers, and M.A. Knovich Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis Kidney Int 73 2008 1062 1068
8. R.L. Garlick, and J.S. Mazer The principal site of nonenzymatic glycosylation of human serum albumin in vivo J Biol Chem 258 1983 6142 6146
9. R. Bucala, K.J. Tracey, and A. Cerami Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes J Clin Invest 87 1991 432 438
10. A.M. Schmidt, M. Hasu, D. Popov, J.H. Zhang, J.S. Chen, and D. Yan Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins Proc Natl Acad Sci U S A 91 1994 8807 8811
11. S.D. Yan, A.M. Schmidt, G.M. Anderson, J. Zhang, J. Brett, and Y.S. Zou Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins J Biol Chem 269 1994 9889 9897
12. A.W. Stitt The role of advanced glycation in the pathogenesis of diabetic retinopathy Exp Mol Pathol 75 2003 95 108
13. D.S. Fosmark, P.A. Torjesen, B.K. Kilhovd, T.J. Berg, L. Sandvik, and K.F. Hanssen Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus Metabolism 55 2006 232 236
14. H.P. Hammes, A. Alt, T. Niwa, J.T. Clausen, R.G. Bretzel, and M. Brownlee Differential accumulation of advanced glycation end products in the course of diabetic retinopathy Diabetologia 42 1999 728 736
15. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, and Y. Kaneda Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
16. X. Du, T. Matsumura, D. Edelstein, L. Rossetti, Z. Zsengelle, and C. Szabo Inhibition of GAPDH activity by poly (ADPribose) polymerase activates three major pathways of hyperglycaemic damage in endothelial cells J Clin Investig 112 2003 1049 1057
17. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 44 Suppl. 2 2001 S14 S21
18. K. Gu, C.C. Cowie, and M.I. Harris Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993 Diabetes Care 21 1998 1138 1145
19. A.M. Schmidt, S.D. Yan, J.L. Wautier, and D. Stern Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis Circ Res 84 1999 489 497
20. R. Bucala, Z. Makita, G. Vega, S. Grundy, A. Cerami, and H. Vlassara Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency Proc Natl Acad Sci U S A 91 1994 9441 9445
21. C. Esposito, H. Gerlach, J. Brett, D. Stern, and H. Vlassara Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties J Exp Med 170 1989 1387 1407
22. H. Vlassara Advanced glycation end-products and atherosclerosis Ann Med 28 1996 419 426
23. J.W. Hartog, A.A. Voors, S.J. Bakker, A.J. Smit, and D.J. van Veldhuisen Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications Eur J Heart Fail 9 2007 1146 1155
24. M. Galderisi Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography J Am Coll Cardiol 48 2006 1548 1551
25. R. Meerwaldt, T. Links, C. Zeebregts, R. Tio, J.L. Hillebrands, and A. Smit The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes Cardiovasc Diabetol 7 2008 29
26. M.P. Cohen, E. Shea, S. Chen, and C.W. Shearman Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor beta 1 production in macrophage RAW cells J Lab Clin Med 141 2003 242 249
27. H.M. Lander, J.M. Tauras, J.S. Ogiste, O. Hori, R.A. Moss, and A.M. Schmidt Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress J Biol Chem 272 1997 17810 17814
28. Y. Hattori, H. Kakishita, K. Akimoto, M. Matsumura, and K. Kasai Glycated serum albumin-induced vascular smooth muscle cell proliferation through activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by protein kinase C Biochem Biophys Res Commun 281 2001 891 896
29. X. Fan, R. Subramaniam, M.F. Weiss, and V.M. Monnier Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kappaB and intracellular reactive oxygen species formation Arch Biochem Biophys 409 2003 274 286
30. H. Nakayama, S. Taneda, S. Kuwajima, S. Aoki, Y. Kuroda, and K. Misawa Production and characterization of antibodies to advanced glycation products on proteins Biochem Biophys Res Commun 162 1989 740 745
31. H.V. Roohk, and A.R. Zaidi A review of glycated albumin as an intermediate glycation index for controlling diabetes J Diabetes Sci Technol 2 2008 1114
32. I.R. Jones, D.R. Owens, S. Williams, R.E. Ryder, A.J. Birtwell, and M.K. Jones Glycosylated serum albumin: an intermediate index of diabetic control Diabetes Care 6 1983 501 503
33. S. Takahashi, H. Uchino, T. Shimizu, A. Kanazawa, Y. Tamura, and K. Sakai Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short term changes in glycemic control Endocr J 54 1 2007 139 144
34. K. Yoshiuchi, M. Matsuhisa, N. Katakarni, Y. Nakatani, K. Sakamoto, and T. Matsuoka Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes Endocr J 55 2008 503 507
35. T. Imai, Y. Oikawa, and A. Shimada Improved monitoring of the hyperglycemic state in type 1 diabetes patients by use of the glycoalbumin/HbA1c ratio Rev Diabetes Study 4 2007 44 54
36. K.D. Kohnert, P. Augstein, P. Heinke, E. Zander, K. Peterson, and E.J. Freyse Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes Diabetes Res Clin Pract 77 2007 420 426
37. Y. Tahara, and K. Shima Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level Diabetes Care 18 1995 440 447
38. R. Kisugi, T. Kouzuma, T. Yamamoto, S. Akizuki, H. Miyamoto, and Y. Someya Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin Clin Chim Acta 382 2007 59 64
39. T. Suwa, A. Ohta, T. Matsui, R. Koganei, H. Kato, and T. Kawata Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM) Endocr J 57 2010 135 140
40. D.E. Goldstein, R.R. Little, R.A. Lorenz, J.I. Malone, D. Nathan, and C.M. Peterson Tests of glycemia in diabetes Diabetes Care 18 6 1995 896 909
41. National glycohemoglobin standardization program. Factors that interfere with GHB (HbA1c) test results. Updated 4/08. http://www.ngsp.org/prog/factors.htm.
42. J.D. Cook, C.A. Finch, and N.J. Smith Evaluation of the iron status of a population Blood 48 3 1976 449 455
43. E. Coban, M. Ozdogen, and A. Timuragaogle Effect of iron deficiency anemia on level of haemoglobin A1c in non diabetic patients Acta Haematol 112 2004 126 128
44. M.S. Eberhardt, D.T. lackland, Wheeler Fc, R.R. German, and S.M. Teutsch Is race related to glycemic control? An assessment of glycosylated haemoglobin in two South Carolina communities J Clin Epidemiol 47 10 1994 1181 1189
45. J.B. Saaddine, A. Fagot-Campagna, D. Rolka, K.M. Narayan, L. Geiss, and M. Eberhardt Distribution of HbA1c levels for children and young adults in the U.S: Third National Health and Nutrition Examination Study Diabetes Care 25 8 2002 1326 1330
46. J.K. Kirk, R.A. Bell, A.G. Bertoni, T.A. Arcury, S.A. Quandt, and D.C. Goff Ehtnic disparities: control of glycemia, blood pressure and LDL cholesterol among US adults with type 2 diabetes Ann Pharmacother 39 9 2005 1489 1501
47. H. Nagayama, M. Inaba, R. Okabe, M. Emoto, E. Ishimura, and S. Okazaki Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test Biomed Pharmacother 63 2009 236 240
48. K. Hashimoto, T. Osugi, S. Noguchi, Y. Morimoto, K. Wasada, and S. Imai A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women Diabetes Care 33 2008 509 511
49. M. Koga, J. Murai, H. Saito, M. Mukai, S. Matsumoto, and S. Kasayama Glycate albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects Ann Clin Biochem 47 2009 39 43